Cargando…

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

BACKGROUND: Recent studies report a lower mortality rate during treatment with long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA in patients with symptomatic chronic obstructive pulmonary disease (COPD) and a history of exacerbatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miravitlles, Marc, Verhamme, Katia, Calverley, Peter M A, Dreher, Michael, Bayer, Valentina, Gardev, Asparuh, de la Hoz, Alberto, Wedzicha, Jadwiga, Price, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924530/ https://www.ncbi.nlm.nih.gov/pubmed/35309285 http://dx.doi.org/10.2147/COPD.S350167

Ejemplares similares

Stepwise management of COPD: What is next after bronchodilation?
por: Miravitlles, Marc, et al.
Publicado: (2023)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
por: Singh, Dave, et al.
Publicado: (2020)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

The role of inhaled and/or nasal corticosteroids on the bronchodilator response
por: Lee, Ju Kyung, et al.
Publicado: (2010)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Impact of PIF, Inhalation Technique and Medication Adherence on Health Status and Exacerbations in COPD: Protocol of a Real-World Observational Study (PIFotal COPD Study)
por: Leving, Marika, et al.
Publicado: (2021)

Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD
por: Paschalaki, Koralia, et al.
Publicado: (2022)

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial
por: Choudhury, Aklak B, et al.
Publicado: (2007)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
por: Miravitlles, Marc, et al.
Publicado: (2022)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
por: Miravitlles, Marc, et al.
Publicado: (2021)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2013)

Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions
por: Clouse, Brian J., et al.
Publicado: (2016)

Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources
por: Alhaider, S.A., et al.
Publicado: (2014)

Inhaled Bronchodilators and Corticosteroids in the Management of Bronchiolitis Obliterans due to Allogenic Hematopoietic Stem Cell Transplantation
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2022)

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
por: Magnussen, Helgo, et al.
Publicado: (2021)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis
por: Price, David, et al.
Publicado: (2016)

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited
por: Calverley, Peter
Publicado: (2021)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d63ftkbmn6k5kfd8spjkmm7ro6